The latest market report published by Credence Research, Inc, the global in-vitro fertilization market is set to grow from US$ 15,604.7 million in 2017 to US$ 36,854.0 million by 2026 with a CAGR increase of 10.1 per cent from 2018 to 2026.
Government health institutions and hospitals are actively engaged in providing funding to encourage the freezing of eggs and sperm in order to reduce the rate of multiple pregnancy. Recent technological advances in in vitro fertilization techniques such as Intracytoplasmic Sperm Injection (ICSI) and Assisted Reproductive Technology (ART) are being used to increase the success rate of IVF treatment.
Browse the full report at “In-Vitro Fertilization Market”
The culture media are holding the largest market by instrument in the in vitro fertilization market. The main attributes are increased research activities to improve the culture media and its ability to preserve sperm cells without compromising the quality of the market growth of culture media. Strict regulatory mandates and the urgent need to maintain optimum sterile conditions during IVF treatment will boost market growth for disposable devices at a rapid pace.
Fresh non-donor is a type segment of the in vitro fertilization market due to the high success rate achieved during the first attempt of the treatment protocol. Frozen non-donor will grow quickly in the near future due to an excellent live birth rate, lower miscarriage rate and reduced cases of ectopic pregnancy.
Fertility clinics dominate the end-user segment of the in-vitro fertilization market. Significant increases in couples opting for ART treatment and Gamete Intrafallopian Transfer (GIFT) drive market growth in infertility clinics. Hospitals are showing steady growth due to increased government funding to provide IVF treatment to poor families and increasing public health awareness of infertility treatment.
North America is currently responsible for 35% share and is the leading regional segment for in-vitro fertilization market. Rising prevalence of infertility and existence of highly sophisticated fertility clinics drive the market growth in North America region. As per the research citings of American Society for Reproductive Medicine (ASRM), approximately 11.0% reproductive population suffer with infertility in the United States. Europe holds 30% market share on account of proactive government initiatives of providing financial aid for sponsoring the cost incurred during the IVF cycles. Asia Pacific represents 20% share owing to presence of large target population suffering with infertility. Adoption of sophisticated technology and low treatment cost further bolster the market growth in Asia Pacific region.
Biopharmaceuticals specializing in in-vitro fertilization market are Boston IVF, Cook Medical, Inc., Cooper Surgical, Inc., EMD Serono, Inc., Genea Biomedx, Irvine Scientific, Inc., OvaScience, Inc., Progyny, Inc., Thermo Fisher Scientific, Inc. and Vitrolife AB.
Key Market Movements:
- Rising prevalence of infertility and increasing trend of late child planning
- Technological advancement in the different treatment protocol pertaining to in-vitro fertilization
- Proactive government initiatives to establish fertility clinics and hospitals
By Instrument Type
- Disposable Devices
- Culture Media
- Capital Equipment
- Fresh Donor
- Frozen Donor
- Fresh Non-Donor
- Frozen Non-Donor
By End User Type
- Fertility Clinics
By Geography Segment
- North America (U.S., Rest of North America)
- Europe (U.K., Germany, France, Rest of Europe)
- Asia Pacific (China, Japan, India, Rest of Asia Pacific)
- Rest of the World (Middle East & Africa, Latin America)